MSH2 and cancer: Therefore, clinical germline genetic testing of genes increasing the PDAC risk (including BRCA2, ATM, BRCA1, PALB2, MLH1, MSH2, MSH6, PMS2, CDKN2A, TP53, STK11, and possibly also CHEK2) should be offered to all PDAC patients or at least to those with a positive family cancer history or personal history of multiple primary tumors.